NCT05507541 2025-08-29TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaMayo ClinicPhase 2 Active not recruiting10 enrolled
NCT02890368 2023-04-05Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis FungoidesPfizerPhase 1 Terminated56 enrolled